AU2019393077B2 - Humanized and affinity-matured anti-CEACAM1 antibodies - Google Patents
Humanized and affinity-matured anti-CEACAM1 antibodiesInfo
- Publication number
- AU2019393077B2 AU2019393077B2 AU2019393077A AU2019393077A AU2019393077B2 AU 2019393077 B2 AU2019393077 B2 AU 2019393077B2 AU 2019393077 A AU2019393077 A AU 2019393077A AU 2019393077 A AU2019393077 A AU 2019393077A AU 2019393077 B2 AU2019393077 B2 AU 2019393077B2
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- ceacam1
- antigen
- sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776877P | 2018-12-07 | 2018-12-07 | |
| US62/776,877 | 2018-12-07 | ||
| PCT/US2019/065212 WO2020118295A1 (en) | 2018-12-07 | 2019-12-09 | Humanized and affinity-matured anti-ceacam1 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019393077A1 AU2019393077A1 (en) | 2021-07-29 |
| AU2019393077B2 true AU2019393077B2 (en) | 2026-08-06 |
Family
ID=70973892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019393077A Active AU2019393077B2 (en) | 2018-12-07 | 2019-12-09 | Humanized and affinity-matured anti-CEACAM1 antibodies |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12173066B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3906261A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022513729A (cg-RX-API-DMAC7.html) |
| CN (2) | CN120209144A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019393077B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3121580A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020118295A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3906261A4 (en) * | 2018-12-07 | 2022-12-21 | The Brigham And Women's Hospital, Inc. | HUMANIZED AND AFFINITY MATURED ANTI-CEACAM1 ANTIBODIES |
| IT202100033002A1 (it) * | 2021-12-29 | 2023-06-29 | Diatheva S R L | Anticorpi umani e loro usi |
| JP2025506405A (ja) * | 2022-02-03 | 2025-03-11 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | ヒトceacam1に方向づけられた治療剤に対するコンパニオン診断 |
| WO2023168326A2 (en) * | 2022-03-03 | 2023-09-07 | The Brigham And Women´S Hospital, Inc. | Humanized and affinity-matured anti-ceacam1 antibodies and methods of use |
| CN121335923A (zh) * | 2023-04-13 | 2026-01-13 | 苏州逻晟生物医药有限公司 | Ceacam1靶向抗体及其用途 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015166484A1 (en) * | 2014-04-27 | 2015-11-05 | Ccam Therapeutics Ltd. | Humanized antibodies against ceacam1 |
| US20160176966A1 (en) * | 2009-04-30 | 2016-06-23 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Anti ceacam1 antibodies and methods of using same |
| US9771431B2 (en) * | 2011-10-11 | 2017-09-26 | Ccam Biotherapeutics Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM) |
| WO2018174629A1 (en) * | 2017-03-24 | 2018-09-27 | Mogam Institute For Biomedical Research | Anti-ceacam1 antibody and use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2800311A1 (en) * | 2010-05-11 | 2011-11-17 | Aveo Pharmaceuticals, Inc. | Anti-fgfr2 antibodies |
| ES2753614T3 (es) * | 2011-12-01 | 2020-04-13 | Brigham & Womens Hospital Inc | Anticuerpos recombinantes anti-CEACAM1 para terapia contra el cáncer |
| ES2980417T3 (es) * | 2013-11-25 | 2024-10-01 | Famewave Ltd | Composiciones que comprenden anticuerpos anti-CEACAM1 y anti-PD para la terapia del cáncer |
| WO2016120331A1 (de) | 2015-01-28 | 2016-08-04 | Karl Sebastian Lang | Agonistische anti-cd66cd66 antikörper für die antiviralen therapie |
| US20180153986A1 (en) * | 2015-04-24 | 2018-06-07 | The Brigham And Women's Hospital, Inc. | Interactions between ceacam and tim family members |
| EP3906261A4 (en) * | 2018-12-07 | 2022-12-21 | The Brigham And Women's Hospital, Inc. | HUMANIZED AND AFFINITY MATURED ANTI-CEACAM1 ANTIBODIES |
-
2019
- 2019-12-09 EP EP19893377.2A patent/EP3906261A4/en active Pending
- 2019-12-09 AU AU2019393077A patent/AU2019393077B2/en active Active
- 2019-12-09 US US17/311,258 patent/US12173066B2/en active Active
- 2019-12-09 JP JP2021532041A patent/JP2022513729A/ja not_active Withdrawn
- 2019-12-09 WO PCT/US2019/065212 patent/WO2020118295A1/en not_active Ceased
- 2019-12-09 CN CN202510125669.1A patent/CN120209144A/zh active Pending
- 2019-12-09 CN CN201980091531.7A patent/CN113840839B/zh active Active
- 2019-12-09 CA CA3121580A patent/CA3121580A1/en active Pending
-
2024
- 2024-10-10 JP JP2024177850A patent/JP2025016505A/ja active Pending
- 2024-11-19 US US18/952,149 patent/US20250074980A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160176966A1 (en) * | 2009-04-30 | 2016-06-23 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Anti ceacam1 antibodies and methods of using same |
| US9771431B2 (en) * | 2011-10-11 | 2017-09-26 | Ccam Biotherapeutics Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM) |
| WO2015166484A1 (en) * | 2014-04-27 | 2015-11-05 | Ccam Therapeutics Ltd. | Humanized antibodies against ceacam1 |
| WO2018174629A1 (en) * | 2017-03-24 | 2018-09-27 | Mogam Institute For Biomedical Research | Anti-ceacam1 antibody and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022513729A (ja) | 2022-02-09 |
| WO2020118295A1 (en) | 2020-06-11 |
| AU2019393077A1 (en) | 2021-07-29 |
| US12173066B2 (en) | 2024-12-24 |
| CN120209144A (zh) | 2025-06-27 |
| EP3906261A4 (en) | 2022-12-21 |
| US20220025040A1 (en) | 2022-01-27 |
| CN113840839A (zh) | 2021-12-24 |
| EP3906261A1 (en) | 2021-11-10 |
| CN113840839B (zh) | 2025-02-14 |
| US20250074980A1 (en) | 2025-03-06 |
| CA3121580A1 (en) | 2020-06-11 |
| JP2025016505A (ja) | 2025-02-04 |